Cetylmyristoleate and arthritis pain relief have been reviewed for some time now. Might cetyl myristoleate be what you've been looking for? So what is this cetylmyristoleate compound?
Harry W. Diehl has dedicated his research to finding a cure for arthritis. He has studied the disease for 60 years, first at NIH, and then at this home lab, ultimately discovering the compound cetylmyristoleate. A report on cetyl myristoleate was published in the Journal of Pharmaceutical Sciences, March 1994. Discovery of cetylmyristoleate arose from Diehl's observation that Swiss albino mice are immune to all forms of arthritis. Diehl successfully isolated the substance in the mice, cetylmyristoleate, which makes them immune.
In his research, Diehl injected rats with an arthritis-inducing material that caused severe manifestation of arthritis in their legs and tails. After Diehl injected them with cetylmyristoleate, the rats were cured. The swelling left the joints and their crippled limbs began to straighten. For all the details see below:
As for dosage, Diehl said, "I have found in my research that people respond to various amounts. I took two capsules four years ago at the onset of sever pain. I was cured of arthritis in my heel, knees, and hands. Also, I have no more headaches or bronchitis. Most people start with four capsules (taken between meals). After a period of four to six weeks, three more capsules are taken. This can vary depending on a person's condition and weight."
Cetylmyristoleate has not been FDA approved, nor is it a cure for arthritis. Research does suggest that it can improve symptoms. One study found CMO to improve the symptoms of rheumatoid and osteoarthritis, ankylosing spondylitis, Reiter's syndrome, Behcet's syndrome, Sjogren's syndrome and psoriasis.
Like everything else, cetyl myristoleate does not work 100% of the time. Failure to work can be associated with failure to follow the dietary recommendations; failure to take a sufficient amount of cetyl myristoleate; failure of the liver to uptake and respond to the CMO; and/or, misdiagnosis of the problem.